GSK-203162

Study Sponsor: GSK

Study Title

An escalating dose, randomized, placebo-controlled, incomplete-block, 2-period cross-over study to assess the dose response for topical efficacy via airway responsiveness to adenosine-5'-monophosphate (AMP) challenge and the dose response for systemic activity via 24h plasma cortisol suppression and thereby the relative therapeutic index for fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD) in asthmatic subjects

Medicine or Vaccine (generic name)

fluticasone furoate; fluticasone propionate

Sponsor Identification Number

203162

Trial Registry Identification Number(#'s)

NCT02991859 2016-003002-14

Medical Condition

Asthma

Phase

Phase 2

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=203162

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT02991859

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-003002-14

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

The data for this study is available in CDISC format.

Date Added to this Site

June 2020